Abstract
This new strategic report from Espicom provides a comprehensive review of
current and future treatments for major gastrointestinal therapy areas:
inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and
gastro-oesophageal reflux disease (GORD).
- Unique market share and 5-year sales forecasts for leading products &
prospects
- A comprehensive examination of major gastrointestinal therapy areas
- Critical competitive evaluation and scoring of current and up and coming
products
THE REPORT COVERS MAJOR DISEASE AREAS
Inflammatory bowel disease (Crohn' s disease & ulcerative colitis) Irritable
bowel syndrome Gastro-oesophageal reflux disease (GORD)
THE FACTS
Risk factors, how the disease affects patients, diagnosis and stages of the
disease
PATIENT STATISTICS
Prevalence in the US, Europe and Japan Diagnosis rates
CURRENT TREATMENT OPTIONS
Interventions by type Unique five point competitive assessment and scoring of
current therapies and companies involved Sales forecasts for key products to
2012
R&D: DRUGS IN PHASE II/III
Focus on new classes of drugs and the companies involved Unique competitive
assessment and scoring of new therapies and companies involved 5-year sales
forecasts for key products from year of launch
Providing…
- Detailed analysis and 5-year forecasts for current leading products by
value
- A detailed review and assessment of up and coming products
- Unique product evaluation and scoring
- An examination of the current understanding of IBD, IBS and GORD
Table of Contents
- Foreword
- Executive Summary
- Inflammatory Bowel Disease
- What is inflammatory bowel disease?
- Risk factors in the development of IBD
- Where in the world?
- The IBD therapy market
- IBD management
- Current treatment options
- Aminosalicylates
- Sulphasalazine
- Oral Mesalamine
- Topical Mesalamine
- Olsalazine
- Balsalazide
- Corticosteroids
- Prednisone
- Budesonide
- Hydrocortisone
- Immunosuppressants
- 6-mercaptopurine
- Azathioprine
- Cyclosporine
- Methotrexate
- Tumour necrosis factor alpha inhibitors
- What' s in the pipeline?
- Potential new drugs for IBD
- Competitor ratio analysis
- Tumour necrosis factor alpha inhibitors
- Remicade (infliximab)
- Sales forecast
- Clinical trial results
- Paediatric Crohn' s Disease
- Ulcerative Colitis
- Humira (adalimumab)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Cimzia (certolizumab pegol)
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- PRECiSE clinical trial programme
- RDP58 (delmitide)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Golimumab
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Cell adhesion molecule inhibitors
- Tysabri (natalizumab)
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Alicaforsen
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Firategrast (SB683699)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- MLN0002
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Novel corticosteroids
- COLAL-PRED (prednisolone)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- T-cell modulators
- Nuvion (visilizumab)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Orencia (abatacept)
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Immune system modulators
- Alequel
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Interleukin inhibitors
- ABT-874
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- STA-5326
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- MAP kinase inhibitors
- Semapimod
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Others
- Traficet-EN
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- AST-120
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- HMPL-004
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Promising early-stage development candidates
- Irritable Bowel Syndrome
- What is irritable bowel syndrome?
- Where in the world?
- The IBS therapy market
- IBS management
- Current treatment options
- Antispasmodics
- Laxatives
- Antidiarrhoeal agents
- Antidepressants
- Serotonergic agents
- What' s in the pipeline?
- Potential new drugs for IBS
- Competitor ratio analysis
- Serotonergic Agents
- Lotronex (alosetron)
- Zelnorm (tegaserod)
- Sales forecast
- Clinical trial results
- IBS with mixed bowel pattern
- DDP225
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- DDP733
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Renzapride
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Others
- Amitiza (lubiprostone)
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Linaclotide acetate
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Dexloxiglumide
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Dextofisopam
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Xifaxan (rifaximin)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Crofelemer
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Gastro-oesophageal Reflux Disease
- What is gastro-oesophageal reflux disease?
- The GORD therapy market
- GORD management
- H2 receptor antagonists
- Pepcid/Gaster (famotidine)
- Zantac (ranitidine)
- Axid (nizatidine)
- Tagamet (cimetidine)
- Proton pump inhibitors
- AcipHex/Pariet (rabeprazole)
- Nexium (esomeprazole)
- Prevacid (lansoprazole)
- Losec/Prilosec (omeprazole)
- Protonix (pantoprazole)
- What' s in the pipeline?
- Competitor ratio analysis
- Potential new drugs for GORD
- ATI-7505
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- DDP733
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- OX 17
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- ADX10059
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- XP19986
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- SOURCES
- Espicom Sources
- Others
List of Tables
- Genes associated with IBD
- IBD patient forecasts 2005-2012
- Currently available aminosalicylates
- Currently available corticosteroids
- Immunosuppressants currently used in IBD
- Drugs in developmentfor IBD
- Competitor ratio analysis summary
- Remicade sales, 2002-2006 (US$ millions)
- Humira sales, 2003-2006 (US$ millions)
- Currently available antidepressants
- Drugs in development for IBS
- Competitor ratio analysis summary
- Competitor Ratio Score: 42
- Sales of leading drugs used in GORD management (US$ millions)
- Approved H2 receptor antagonists
- Gaster Sales, 2003-2007 (¥ & US$ million)
- Zantac sales, 2002-2006 (£ & US$ million)
- Approved proton pump inhibitors
- AcipHex/Pariet sales, 2002-2006 (¥ & US$ million)
- Nexium sales, 2002-2006 (US$ million)
- Prevacid/Takepron sales, 2002-2006 (¥ & US$ million)
- Losec/Prilosec sales, 2002-2006 (US$ million)
- Protonix/Pantozol sales, 2002-2006 (EUR & US$ million)
- Drugs in development for GORD
- Competitor ratio analysis summary
List of Figures
- IBD prevalence 2007
- Drugs in clinical development for IBD by activity
- Remicade projected sales, 2006-2012 (US$ million)
- Humira projected sales 2006-2012 (US$ millions)
- Cimzia projected sales 2008-2012 (US$ millions)
- Golimumab projected sales, 2010-2014 (US$ million)
- ABT-874 projected sales, 2009-2014 (US$ millions)
- Amitiza, projected sales 2006-2012 (US$ millions)
- Gaster projected sales, 2007-2012 (US$ Million)
- Zantac projected sales, 2006-2012 (US$ million)
- AcipHex/Pariet projected sales, 2007-2012 (US$ million)
- Nexium projected sales, 2006-2012 (US$ million)
- Prevacid/Takepron projected sales, 2006-2012 (US$ million)
- Losec/Prilosec projected sales, 2006-2012 (US$ million)
- Protonix/Pantozol projected sales, 2006-2012 (US$ million)
医薬品
その他のカテゴリ
FAQ